In a second phase of the study, researchers then gave a group of 79 chronic migraine patients either the 200 mg THC-CBD combination or a 25mg dose of amitriptyline – a tricyclic antidepressant commonly used to treat migraine.
After three months of daily treatment, researchers found that the group taking the THC-CBD combination had a 40.4% reduction in migraine attacks, which was slightly better than the amitriptyline group (40.1%).
The cannabinoids reduced migraine pain intensity by an average of 43.5 percent. Female patients also reported a decline in stomach ache, colitis and musculoskeletal pain.
“We were able to demonstrate that cannabinoids are an alternative to established treatments in migraine prevention,” said Nicoldi, who recently presented her findings at the 3rd Congress of the European Academy of Neurology in Amsterdam.